ReShape Lifesciences Tweets 'Will #GLP1 Medications Replace #weightloss #surgery? According to ReShape CEO, Paul Hickey, via @InvestingCom, #GLP1s Are a Very Attractive Tool to Fight #obesity. However, Our ReShape Lap-Band Is Safe and Less Invasive'

ReShape Lifesciences Tweets 'Will #GLP1 Medications Replace #weightloss #surgery? According to ReShape CEO, Paul Hickey, via @InvestingCom, #GLP1s Are a Very Attractive Tool to Fight #obesity. However

BenzingaApr 4 01:39

ReShape Lifesciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Yahoo FinanceApr 3 19:25

ReShape Lifesciences 2023 Rev $8.7M >RSLS

ReShape Lifesciences 2023 Rev $8.7M >RSLS

Dow JonesApr 2 04:13

ReShape Lifesciences 2023 R&D Expenses $2.3M >RSLS

ReShape Lifesciences 2023 R&D Expenses $2.3M >RSLS

Dow JonesApr 2 04:13

ReShape Lifesciences Expects 2024 Operating Expenses To Decrease By More Than 50% Compared to 2023; Reaffirming Commitment To Profitability

ReShape Lifesciences Expects 2024 Operating Expenses To Decrease By More Than 50% Compared to 2023; Reaffirming Commitment To Profitability

BenzingaApr 2 04:09

Reshape Lifesciences FY23 Sales $8.678M Miss $8.904M Estimate

Reshape Lifesciences (NASDAQ:RSLS) reported quarterly sales of $8.678 million which missed the analyst consensus estimate of $8.904 million by 2.54 percent.

BenzingaApr 2 04:08